163 related articles for article (PubMed ID: 34575390)
21. Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian Ankylosing Spondylitis Patients.
Bansal N; Duggal L; Jain N
J Clin Diagn Res; 2017 Sep; 11(9):OC06-OC09. PubMed ID: 29207750
[TBL] [Abstract][Full Text] [Related]
22. The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.
Tsang HHL; Chung HY
J Clin Rheumatol; 2017 Aug; 23(5):267-272. PubMed ID: 28661926
[TBL] [Abstract][Full Text] [Related]
23. [The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
DU XN; Li Y; Zhang SL; Zhu J; Huang F
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):206-9. PubMed ID: 22781894
[TBL] [Abstract][Full Text] [Related]
24. BASDAI cut-off values corresponding to ASDAS cut-off values.
Kwon OC; Park MC
Rheumatology (Oxford); 2022 May; 61(6):2369-2374. PubMed ID: 34558610
[TBL] [Abstract][Full Text] [Related]
25. Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-α blockers.
Nam EJ; Lee WK
Medicine (Baltimore); 2020 Oct; 99(41):e22668. PubMed ID: 33031332
[TBL] [Abstract][Full Text] [Related]
26. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study).
Sellas I Fernandez A; Juanola Roura X; Alonso Ruiz A; Rosas J; Medina Luezas J; Collantes Estevez E; Abad Hernández MÁ; Carrasco Benitez V; Fisac C
Rheumatol Int; 2017 Nov; 37(11):1817-1823. PubMed ID: 28918450
[TBL] [Abstract][Full Text] [Related]
28. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
29. Gender difference in ASAS HI among patients with ankylosing spondylitis.
Chen HH; Chen YM; Lai KL; Hsieh TY; Hung WT; Lin CT; Tseng CW; Tang KT; Chou YY; Wu YD; Huang CY; Hsieh CW; Huang WN; Chen YH
PLoS One; 2020; 15(7):e0235678. PubMed ID: 32645080
[TBL] [Abstract][Full Text] [Related]
30. The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis.
Chen YH; Huang WN; Chen YM; Lai KL; Hsieh TY; Hung WT; Lin CT; Tseng CW; Tang KT; Chou YY; Wu YD; Huang CY; Hsieh CW; Chen YJ; Liao YW; Chen HH
Front Med (Lausanne); 2022; 9():856654. PubMed ID: 35652077
[TBL] [Abstract][Full Text] [Related]
31. Use of Quantitative Vertebral Bone Marrow Fat Fraction to Assess Disease Activity and Chronicity in Patients with Ankylosing Spondylitis.
Ahn GY; Koo BS; Joo KB; Kim TH; Lee S
Korean J Radiol; 2021 Oct; 22(10):1671-1679. PubMed ID: 34402239
[TBL] [Abstract][Full Text] [Related]
32. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
[TBL] [Abstract][Full Text] [Related]
33. Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis.
Castrejón I; Pincus T; Wendling D; Dougados M
RMD Open; 2016; 2(2):e000235. PubMed ID: 27486525
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal Association Between Trabecular Bone Loss and Disease Activity in Axial Spondyloarthritis: A 4-year Prospective Study.
Kang KY; Ju JH; Park SH; Hong YS
J Rheumatol; 2020 Sep; 47(9):1330-1337. PubMed ID: 31732556
[TBL] [Abstract][Full Text] [Related]
35. Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care.
Park SH; Choe JY; Kim SK; Lee H; Castrejón I; Pincus T
J Clin Rheumatol; 2015 Sep; 21(6):300-4. PubMed ID: 26308349
[TBL] [Abstract][Full Text] [Related]
36. Bath Ankylosing Spondylitis Disease Activity Index is Associated With the Quality of Sleep in Ankylosing Spondylitis Patients.
Song BW; Jeong HJ; Kim BY; Cho YW; Son CN; Kim SS; Kim SH
J Rheum Dis; 2021 Jul; 28(3):143-149. PubMed ID: 37475993
[TBL] [Abstract][Full Text] [Related]
37. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
Sieper J; van der Heijde D; Dougados M; Brown LS; Lavie F; Pangan AL
Ann Rheum Dis; 2012 May; 71(5):700-6. PubMed ID: 22128084
[TBL] [Abstract][Full Text] [Related]
38. CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up.
Berg IJ; Semb AG; van der Heijde D; Kvien TK; Olsen IC; Dagfinrud H; Provan SA
Ann Rheum Dis; 2015 Aug; 74(8):1562-6. PubMed ID: 25795906
[TBL] [Abstract][Full Text] [Related]
39. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
Park JH; Kwon OC; Park MC
Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
[TBL] [Abstract][Full Text] [Related]
40. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
